DNA damage and replication checkpoints mediated by the ATR-CHEK1 pathway are key to the maintenance of genome stability, and both ATR and CHEK1 have been proposed as potential breast cancer susceptibility genes. Many novel variants recently identified by the large resequencing projects have not yet been thoroughly tested in genome-wide association studies for breast cancer susceptibility. We therefore used a tagging SNP (tagSNP) approach based on recent SNP data available from the 1000 genomes projects, to investigate the roles of ATR and CHEK1 in breast cancer risk and survival. ATR and CHEK1 tagSNPs were genotyped in the Sheffield Breast Cancer Study (SBCS; 1011 cases and 1024 controls) using Illumina GoldenGate assays. Untyped SNPs were imputed using IMPUTE2, and associations between genotype and breast cancer risk and survival were evaluated using logistic and Cox proportional hazard regression models respectively on a per allele basis. Significant associations were further examined in a meta-analysis of published data or confirmed in the Utah Breast Cancer Study (UBCS). The most significant associations for breast cancer risk in SBCS came from rs6805118 in ATR (p=7.6x10 -5 ) and rs2155388 in CHEK1 (p=3.1x10 -6 ), but neither remained significant after meta-analysis with other studies. However, meta-analysis of published data revealed a weak association between the ATR SNP rs1802904 (minor allele frequency is 12%) and breast cancer risk, with a summary odds ratio (confidence interval) of 0. 90 (0.83-0.98) [p=0.0185] for the minor allele. Further replication of this SNP in larger studies is warranted since it is located in the target region of 2 microRNAs. No evidence of any survival effects of ATR or CHEK1 SNPs were identified. We conclude that common alleles of ATR and CHEK1 are not implicated in breast cancer risk or survival, but we cannot exclude effects of rare alleles and of common alleles with very small effect sizes.
Introduction
Despite the successes of the genome-wide association studies (GWAS) in identifying breast cancer susceptibility loci, the level of breast cancer risk explained by these susceptibility loci remains modest [1] . Good coverage of genetic markers, usually single nucleotide polymorphisms (SNPs) that sufficiently represent the surrounding variants through linkage disequilibrium (LD), is essential to a successful screening of susceptibility loci. So far, not all regions have been well captured, and more genetic markers may be needed. For example, novel disease susceptibility loci have been identified from the meta-analysis of several GWAS together [2, 3] , suggesting that some loci are not well captured in the initial GWAS discovery stage, partly due to a lack of power. The 1000 genomes project is a good resource to complement the incomplete coverage of GWAS chips, in which low coverage whole-genome shotgun sequencing and targeted sequencing of known exons has been carried out on a large number of samples [4] . Many of the resulting novel variants have not yet been thoroughly tested in GWAS.
The ATR-CHEK1 DNA damage response pathway is key for maintenance of genome stability. ATR recognises DNA singlestrand breaks, and activates CHEK1 to initiate cell cycle arrest and DNA replication inhibition, the repression of cyclin proteins, and the activation of Fanconi Anemia proteins for DNA repair [5] . The close cross-talk between CHEK1 and BRCA1, the breast cancer tumour suppressor gene, at the G2/M checkpoint [6] suggests the potential importance of this pathway in breast cancer.
To date, a small number of gene-based association studies have been carried out to investigate the roles of ATR and CHEK1 as breast cancer susceptibility genes, using a tagging SNP (tagSNPs) approach. In these studies a subset of representative SNPs were chosen from previous reference panels that are less complete than those currently available [7] [8] [9] [10] [11] [12] . Inconclusive evidence was reported for the ATR and CHEK1 SNPs in association with breast cancer risk [7] [8] [9] [10] [11] [12] . In addition, associations with survival following breast cancer diagnosis are examined in two of these studies, and null findings were reported [8, 12] . Here, we have carried out a more detailed study of the role of the ATR and CHEK1 in breast cancer risk and survival based on the more complete resources now available from the 1000 genomes project.
Materials and Methods

Ethics Statement
All Sheffield and Utah participants gave written informed consent for the collection of data and blood samples. The Sheffield and Utah studies were approved by South Sheffield Research Ethics Committee and University of Utah Institutional Review Board, respectively.
Study populations
The Sheffield Breast Cancer Study (SBCS) recruited histologically confirmed breast cancer patients from surgical outpatient clinics in the Royal Hallamshire Hospital, Sheffield and Rotherham District Hospital from 1998 to 2005. Women aged 50-60 years attending the mammography breast screening service in Sheffield between October 2000 and January 2004 were drawn as control subjects if there was no evidence of breast lesions in their mammograms. Samples from 1011 cases and 1024 controls were available for genotyping. Cases and controls were all resident in the Sheffield area and of northern European ancestry. Information regarding histology, grade, lymph node status, and tumour size was obtained from the medical records and histopathology reports. Vital status was updated as of September 2009 by linking hospital records and the Trent Cancer Registry [13, 14] .
The Utah Breast Cancer Study (UBCS) identified breast cancer patients from high risk cancer pedigrees, identified through the Utah Population database linked to the Utah Cancer Registry, and excluded cancer patients having BRCA1 or BRCA2 mutations. Control subjects comprised distantly related and unrelated cancer-free individuals matched on sex, birth year (within 5 years) and birthplace [15] . The UBCS comprised 898 breast cases and 899 controls.
TagSNP selection
TagSNPs were selected from the common SNPs [minor allele frequency (MAF) ≧2%] identified from the whole-genome sequencing of 60 unrelated individuals of European ancestry in Utah (CEU low-coverage pilot, 2010-07 release) from the 1000 genomes project [4] . SNPs with Illumina GoldenGate assay design scores of ≧0.8 were given priority as tagSNPs if they were genotyped in the previously reported studies [7] [8] [9] . Also, priority was given to SNPs in microRNA target sites as predicted by MicroRNA.org (2010-08 release) [16] , since microRNA target SNPs have been shown to affect gene expression by the disruption of the interaction between microRNA and its target mRNA [17] . Aggressive 2-3 marker tagging at r 2 ≧ 0.8 was used to select tagSNPs based on the hg19 genomic intervals on chromosome 3:142118077-142347668 and chromosome 11: 125445035-125596150 containing the ATR and CHEK1 genes respectively, plus 50kb upstream and downstream of each gene, by use of the Haploview 4.1 software [18] . The initial tagSNP set (32 ATR and 40 CHEK1 tagSNPs) was further supplemented with tags for the known common variants in the exon targeted capture sequencing data on 90 CEU and 43 British from England and Scotland (GBR) from the 1000 genomes project (exon pilot; 2010-03 release) [4] . An additional 8 ATR and 10 CHEK1 tagSNPs were thus identified, resulting in a total of 40 ATR and 50 CHEK1 SNPs for genotyping. The details of the source of tagSNPs and priority (publications or microRNA target sites) are given in Table S1 in File S1.
Genotyping & quality control
Genotyping was carried out in 96-well microtiter plates using custom Illumina GoldenGate VeraCode assays on the Illumina BeadXpress platform. Genotypes were determined by the genotyping module (1.94) of the Illumina GenomeStudio suite (version 2011.1). Genotyping quality was examined by SNP call rate, duplicate concordance and the Hardy-Weinberg equilibrium (HWE) test in controls. Eight ATR and 6 CHEK1 tagSNPs were excluded from the analysis having call rates of <90%, duplicate concordance of <98%, HWE p value of < 10 -3 or monomorphism (Table S2 in File S1). Further to this, samples called on < 80% of SNPs were also excluded. The final SBCS data consisted of 32 ATR and 44 CHEK1 tagSNPs on 955 cases and 955 controls. The selected tagSNPs capture 74.9% of ATR and 71.7% of CHK1 SNPs at r 2 of ≧ 0.9, with mean r 2 of 88% and 87.4% respectively for SNPs with minor allele frequencies at least 0.02, based on the 1000 genomes 2011-05 release.
Statistical analysis
Imputation. Missing genotypes were imputed for typed SNPs and untyped variants using Impute2 [19, 20] based on the 1000 genomes phase I reference panel with singleton variants filtered out. Variants with European MAF ≧ 2% within the ATR and CHEK1 regions were imputed, and included in the subsequent analysis if their imputation information score was greater than 0.8. After filtering, the numbers of eligible imputed variants were 454 and 434 for the ATR and CHEK1 regions, respectively.
Breast cancer risk . Allelic dosage for the minor allele was calculated for typed SNPs and imputed variants, to take account of imputation uncertainty, and was included in a logistic regression model for each SNP. To screen for association with breast cancer risk, allelic odds ratio (OR), 95% confidence interval (CI) and Wald p values were calculated for each SNP using the logistic regression model. Meta analysis . A literature search was conducted using HuGE Navigator [21] . The terms "ATR or CHEK1" were used, and the resulting publications were limited to breast neoplasms and gene candidate studies on Europeans. Meta-analysis was then carried out for the published SNPs that were also genotyped in our study. We also included data from a genomewide association study based on postmenopausal women in Nurses' Health Study (Cancer Genetic Markers of Susceptibility, CGEMS) [22] if data on relevant SNPs were available. Study specific ORs were pooled by means of both fixed and random models, and the homogeneity of ORs across the centres was evaluated by both Cochran's Q test and I 2 measurement implemented in the R metafor package [23] .
Breast cancer survival . The Cox proportional hazard model, including age at diagnosis and the left-censoring time between study entry and diagnosis, was employed to estimate the hazard ratio (HR) and 95% CI for each SNP for breast cancer survival. Further adjustment was carried out for lymph node status (binary variable; negative, positive), grade (categorical variable; 1, 2, 3), and tumour size (categorical variable; <2, 2-5, >5 cm) for any significant SNPs. All reported p values are nominal and two-sided. All statistical tests were performed using R 2.15.2.
Results
Breast cancer risk
There are a total of 486 SNPs (32 typed SNPs and 454 imputed variants) in the ATR region (229.5 kb) which also contains the XRN1 and PLS1 genes. Of these variants, the typed ATR SNP rs6805118 yielded the most significant signal for breast cancer risk, with p value of 7.6x10 -5 ( Figure 1 ). The Table S3 in File S1).
For the chromosome 11: 125445035-125596150 region containing the EI24, STT3A, CHEK1 and ACRV1 genes, the most significant association came from the typed rs2155388 SNP at p value of 3.1x10 -6 ( Figure 2) , with an allelic effect of OR of 1.43 (95% CI: 1.23-1.65) ( Table S4 in File S1). This SNP mapped to the etoposide induced 2.4 (EI24) gene. The EI24 protein is involved in p53-mediated apoptosis. There were some other nominally significant associations in the intergenic region telomeric to the ACRV1 gene (all p ≥5.6x10 -4 ). The top hits in each of the ATR and CHEK1 regions were examined further. The ATR SNP rs6805118 was also genotyped in the SEARCH [8] and NHS [9] studies. We therefore conducted a meta-analysis to combine these data and the results are shown in Figure 3A . We found evidence of heterogeneity among the studies (p het <1x10 -3 ; I 2 =86%). The rs6805118 effect disappeared when all study-specific estimates were combined, with a pooled OR (95% CI) of 0.83 (0.59-1.16) under the random effect model [p=0.277].
The EI24 SNP rs2155388 in the CHEK1 region has not been examined in published data. We therefore carried out further genotyping in UBCS, and genotypes were successfully obtained from 859 breast cases and 865 controls. However, the result was not replicated in the UBCS data, with minor allele OR (95% CI) of 1.01 (0.87, 1.17) ( Figure 3B ). Evidence of heterogeneity between studies was found (p het =0.0014, I 2 =90%), and the pooled OR (95% CI) was 1.20 (0.86-1.68) [p=0.29] under the random effect model when both data were combined.
We also carried out a meta-analysis in an effort to increase power to identify any SNPs with small effects. Published data are available for 11 ATR and 11 CHEK1 SNPs. There was no evidence for effects on breast cancer risk for the majority of . Meta-analysis of the association of rs1802904 (ATR region) with breast cancer risk. Fixed effect estimate (pooled OR) is shown, with p value for homogeneity (the Cochran's Q test, p het ) and I-squared for the amount of heterogeneity in parenthesis. DL pooled OR stands for the random effect model derived from the DerSimonian-Laird estimator. MEC: Multiethnic Cohort Study [7] ; SEARCH: Studies of Epidemiology and Risk Factors in Cancer Heredity [8] ; NHS II: Nurses' Health Study (postmenopausal women) [22] ; SBCS: Sheffield Breast Cancer Study. doi: 10.1371/journal.pone.0068578.g004 these, with all ORs close to unity ( Figure S1 for the ATR SNPs; Figure S2 for the CHEK1 SNPs), with the exception of the ATR SNP rs1802904 (Figure 4 ). All studies, including SBCS, showed that the minor allele of rs1802904 was consistently protective for breast cancer by 8-22%, although this association was not statistically significant in any individual study. Study-specific ORs were homogenous for rs1802904 (p het =0.719, I
2 =0%), and the pooled OR were the same in both fixed and random effect models, with OR (95% CI) of 0.90 (0.83-0.98) [p=0.0185].
Breast cancer survival
Vital status post-diagnosis was available for 923 of the 955 SBCS breast cancer subjects. There were 216 deaths during a median of 10.44 years of follow up. Seventy-five percent of the cases are prevalent cases, with a median of 2.32 years between diagnosis and recruitment to study (data not shown). Statistical evidence of survival association was only found for the typed ATR SNP rs11920625 (Table S5 in File S1). The HR (95% CI) was 1.37 (1.03-1.81) [p=0.0297] for the minor allele after adjustment for age at diagnosis and accounting for the left-censoring time. This association was no longer significant after further adjusting for lymph node involvement, grade and tumour size (p=0.064, Table S5 in File S1), and showed a pooled HR (95% CI) of 1.18 (0.91-1.55) [p=0.21; data not shown] when combining with a HR of 1.04 from the SEARCH study [8] . There was no evidence of association between SNPs in the CHEK1 region and breast cancer overall survival (Table  S6 in File S1).
Discussion
ATR in risk and survival
We identified an association between ATR rs6805118 and breast cancer risk in the SBCS discovery set. A protective effect of the minor allele of rs6805118 was also found in the NHS premenopausal women [9] , however the minor allele conferred an increased risk of breast cancer in SEARCH subjects [8] . Meta-analysis of these 3 datasets revealed a high degree of heterogeneity and non-significant pooled OR, suggesting little overall evidence for association with breast cancer risk. In addition, neither SEARCH nor the current study found any evidence for the association of this SNP with survival [8] .
The ATR synonymous rs1802904 SNP was found to be nominally significantly associated with breast cancer risk (p=0.0185) by means of the meta-analysis of the MEC European Americans [7] , NHS postmenopausal women [22] , SEARCH [8] and SBCS data. There was no evidence for heterogeneity (I 2 =0). This SNP lies in the target region of hsamiR-27a and hsa-miR-27b [16] , and in regions of histone modification marks (H3k4me3 and H3k27ac). Therefore, this SNP might exert its effect on breast cancer susceptibility via transcriptional or post-transcriptional gene regulation. Although we cannot rule out the possibility that this is a false positive, further replication is warranted in a larger study.
CHEK1 region in risk and survival
The chromosome 11 interval containing the EI24 and CHEK1 genes is a frequently altered region in breast cancer. A molecular study of breast cancer tumour samples revealed a high frequency of deletions and promoter methylations in the EI24 and CHEK1 genes, and reported poor survival associations for patients with these alterations [24] . These findings highlight the important roles of acquired deletions and inherited epigenetic events of the EI24 and CHEK1 genes in breast cancer progression. The SBCS finding of an rs2155388 effect was not replicated in the UBCS, despite that fact that UBCS had an adequate power of 90% to detect similar associations. Null results were also obtained in our survival analysis. As a result, there was little evidence in our study supporting any inherited sequence variants in the CHEK1 region being associated with breast cancer risk or survival.
In this study, while we can rule out moderate effects of the less common/rare alleles, we are unable to exclude weaker effects of these, for example, odds ratios of less than 1.46 for SNPs with MAF of 5% or less, at 80% power. However, we conclude there is little evidence to support any role for common SNPs in the ATR and CHEK1 regions in breast cancer risk or survival. Figure S1 . Meta-analysis of the typed SNPs in the ATR region. . For each panel, fixed effect estimate (pooled OR) is shown, with p value for homogeneity (the Cochran's Q test, p het ) and I-squared for the amount of heterogeneity in parenthesis. DL pooled OR stands for the random effect model derived from the DerSimonian-Laird estimator. MEC: Multiethnic Cohort Study [7] ; SEARCH: Studies of Epidemiology and Risk Factors in Cancer Heredity [8] 
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